Wednesday, June 10, 2026

pharma · Oral Mucositis · Complex Cardiovascular Surgery With Cardiopulmonary Bypass

CSL Behring

CSL Behring patent portfolio — 25 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Marburg, DE HQ
EMA registrant Type
Company details
Status
Public
HQ
Marburg, DE
Programs
7
Drugs
6
Patents
25
Intelligence · Patents

CSL Behring patents

25 pharmaceutical patents indexed for CSL Behring. 0 expire within 24 months.

CSL Behring has 25 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

Patent portfolio

  1. WO 2022258590

    PROCÉDÉ D'ISOLEMENT DE PLASMINOGÈNE À PARTIR D'UNE FRACTION DE PLASMA SANGUIN

    Expires Wed Dec 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. CA 3198740

    METHODES DE TRAITEMENT D'UN REJET A MEDIATION PAR ANTICORPS

    Expires Thu May 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. AU 2017305856

    Pharmaceutical formulations of C1 esterase inhibitor

    Expires Wed Mar 16 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. DK 2928905

    FREMGANGSMÅDE TIL OPRENSNING AF TERAPEUTISKE PROTEINER

    Expires Sun Mar 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. CA 3072003

    PROCEDE DE FILTRATION VIRALE DU FACTEUR DE VON WILLEBRAND

    Expires Wed Feb 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 2018264111

    PHARMACEUTICAL PRODUCT WITH INCREASED STABILITY COMPRISING IMMUNOGLOBULINS

    Expires Wed Sep 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. CA 3046406

    PRODUIT DE REMPLACEMENT DE FACTEUR DE COAGULATION SANGUINE POUR UTILISATION DANS LE TRAITEMENT PROPHYLACTIQUE OU THERAPEUTIQUE DES HEMORRAGIES

    Expires Wed Aug 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. CA 3034568

    PROCEDE DE PREVENTION D'ATTAQUES AIGUES D'OEDEME DE QUINCKE HEREDITAIRE ASSOCIEES A UNE DEFICIENCE EN INHIBITEUR DE C1 ESTERASE

    Expires Wed Feb 24 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. EP 3193911

    VERBESSERTE FAKTOR-VIII-PRÄPARATIONEN FÜR THERAPEUTISCHE VERWENDUNG UND VERFAHREN ZUR ERHALTUNG DERSELBEN

    Expires Tue Jul 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. EP 3157548

    THERAPIE MIT EINEM FAKTOR-XII-INHIBITOR BEI EINER NEUROTRAUMATISCHEN STÖRUNG

    Expires Tue Apr 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. CA 2977090

    FORMULATIONS PHARMACEUTIQUES DE L'INHIBITEUR D'ESTERASE C1

    Expires Wed Aug 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. EP 3013366

    KOMBINATIONSTHERAPIE MIT EINEM FAKTOR XII-HEMMER UND EINEM C1-HEMMER

    Expires Tue Apr 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. WO 2016020210

    ...

    Expires Wed Feb 06 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. EP 2964255

    BEHANDLUNG UND VORBEUGUNG VON REMOTER ISCHÄMISCHER REPERFUSION

    Expires Tue Jan 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  15. EP 2961422

    THERAPEUTIKUM FÜR FRUCHTWASSEREMBOLIE

    Expires Tue Jan 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  16. US 2015366947

    A Method of Purifying Therapeutic Proteins

    Expires Wed Dec 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  17. CA 2943376

    NEBULISATION D'IMMUNOGLOBULINE

    Expires Wed Oct 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  18. US 2015158906

    Method of Purifying Therapeutic Proteins

    Expires Wed Jun 06 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  19. EP 2846808

    ZUCKERZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON HÄMOPHILIE A UND/ODER VON-WILLEBRAND-SYNDROM

    Expires Tue Mar 13 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  20. US 2014357564

    Von Willebrand Factor Variants Having Improved Factor VIII Binding Affinity

    Expires Wed Nov 29 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  21. EP 2796145

    EIN KOVALENTER KOMPLEX BESTEHEND AUS VON WILLEBRAND UND FAKTOR VIII VERBUNDEN MIT EINER DISULFIDBRÜCKE

    Expires Tue Oct 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  22. EP 2623110

    Faktor-XII-Hemmer zur Behandlung neurologischer Entzündungserkrankungen

    Expires Tue Aug 02 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  23. CA 2858984

    UTILISATION D'UN C1-INHIBITEUR DESTINE AU TRAITEMENT D'UN OEDEME SECONDAIRE DU SYSTEME NERVEUX CENTRAL

    Expires Wed Jun 22 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  24. CA 2852397

    UTILISATION DE GLYCOSAMINOGLYCANES SULFATES POUR AMELIORER LA BIODISPONIBILITE DU FACTEUR VIII

    Expires Wed Apr 20 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  25. CA 2851057

    UTILISATION COMBINEE D'UN GLYCOSAMINOGLYCANE SULFATE ET D'UNE HYALURONIDASE POUR AMELIORER LA BIODISPONIBILITE DU FACTEUR VIII

    Expires Wed Apr 20 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does CSL Behring have?

25 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do CSL Behring patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.